Aurobindo Pharma Ltd has clarified in reference to the observations received from United States Food and Drug Administration (USFDA) after its cGMP inspection at Unit 7 manufacturing facility from September 19-27, 2019.
The inspection ended with 7 observations. The company believes none of the observations are related to data integrity. The Company is confident of addressing these issues within the stipulated timeline.
Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.458.5 as compared to the previous close of Rs. 567.15. The total number of shares traded during the day was 1192950 in over 24274 trades.
The stock hit an intraday high of Rs. 564.25 and intraday low of 450. The net turnover during the day was Rs. 583778895.